In vivo brain levels of acetylcholine and 5-hydroxytryptamine after oleoylethanolamide or palmitoylethanolamide administrations are mediated by PPARα engagement.
PPARα
basal forebrain
lipids
oleoylethanolamide
palmitoylethanolamide
rat
Journal
The European journal of neuroscience
ISSN: 1460-9568
Titre abrégé: Eur J Neurosci
Pays: France
ID NLM: 8918110
Informations de publication
Date de publication:
09 2021
09 2021
Historique:
revised:
06
07
2021
received:
18
05
2021
accepted:
25
07
2021
pubmed:
17
8
2021
medline:
25
9
2021
entrez:
16
8
2021
Statut:
ppublish
Résumé
The peroxisome proliferator-activated receptor alpha (PPARα) is a nuclear receptor that has been linked to the modulation of several physiological functions, including the sleep-wake cycle. The PPARα recognizes as endogenous ligands the lipids oleoylethanolamide (OEA) and palmitoylethanolamide (PEA), which in turn, if systemically injected, they exert wake-promoting effects. Moreover, the activation of PPARα by the administration of OEA or PEA increases the extracellular contents of neurotransmitters linked to the control of wakefulness; however, the role of PPARα activated by OEA or PEA on additional biochemicals related to waking regulation, such as acetylcholine (ACh) and 5-hydroxytryptamine (5-HT), has not been fully studied. Here, we have investigated the effects of treatments of OEA or PEA on the contents of ACh and 5-HT by using in vivo microdialysis techniques coupled to HPLC means. For this purpose, OEA or PEA were systemically injected (5, 10 or 30 mg/kg; i.p.), and the levels of ACh and 5-HT were collected from the basal forebrain, a wake-related brain area. These pharmacological treatments significantly increased the contents of ACh and 5-HT as determined by HPLC procedures. Interestingly, PPARα antagonist MK-886 (30 mg/kg; i.p.) injected before the treatments of OEA or PEA blocked these outcomes. Our data suggest that the activation of PPARα by OEA or PEA produces significant changes on ACh and 5-HT levels measured from the basal forebrain and support the conclusion that PPARα is a suitable molecular element involved in the regulation of wake-related neurotransmitters.
Substances chimiques
Amides
0
Endocannabinoids
0
Ethanolamines
0
Oleic Acids
0
PPAR alpha
0
Palmitic Acids
0
oleoylethanolamide
1HI5J9N8E6
Serotonin
333DO1RDJY
palmidrol
6R8T1UDM3V
Acetylcholine
N9YNS0M02X
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
5932-5950Informations de copyright
© 2021 Federation of European Neuroscience Societies and John Wiley & Sons Ltd.
Références
Anaclet, C., Pedersen, N. P., Ferrari, L. L., Venner, A., Bass, C. E., Arrigoni, E., & Fuller, P. M. (2015). Basal forebrain control of wakefulness and cortical rhythms. Nature Communications, 6, 8744. https://doi.org/10.1038/ncomms9744
Bespalov, A., Wicke, K., & Castagné, V. (2019). Blinding and randomization. In Good research practice in non-clinical pharmacology and biomedicine (pp. 81-100). Springer International Publishing. https://doi.org/10.1007/164_2019_279
Brown, R. E., Basheer, R., McKenna, J. T., Strecker, R. E., & McCarley, R. W. (2012). Control of sleep and wakefulness. Physiological Reviews, 92(3), 1087-1187. https://doi.org/10.1152/physrev.00032.2011
Carta, G., Murru, E., Lisai, S., Sirigu, A., Piras, A., Collu, M., Batetta, B., Gambelli, L., & Banni, S. (2015). Dietary triacylglycerols with palmitic acid in the sn-2 position modulate levels of N-acylethanolamides in rat tissues. PLoS ONE, 10(3), e0120424. https://doi.org/10.1371/journal.pone.0120424
Chen, L., Li, L., Chen, J., Li, L., Zheng, Z., Ren, J., & Qiu, Y. (2015). Oleoylethanolamide, an endogenous PPAR-α ligand, attenuates liver fibrosis targeting hepatic stellate cells. Oncotarget, 6(40), 42530-42540. https://doi.org/10.18632/oncotarget.6466
Cissé, Y., Toossi, H., Ishibashi, M., Mainville, L., Leonard, C. S., Adamantidis, A., & Jones, B. E. (2018). Discharge and role of acetylcholine pontomesencephalic neurons in cortical activity and sleep-wake states examined by optogenetics and juxtacellular recording in mice. eNeuro, 5(4), ENEURO.0270-18.2018. https://doi.org/10.1523/ENEURO.0270-18.2018
Clark, M., & Bracci, E. (2018). Dichotomous dopaminergic control of ventral pallidum neurons. Frontiers in Cellular Neuroscience, 12, 260. https://doi.org/10.3389/fncel.2018.00260
Donvito, G., Bagdas, D., Toma, W., Rahimpour, E., Jackson, A., Meade, J. A., AlSharari, S., Kulkarni, A. R., Ivy Carroll, F., Lichtman, A. H., Papke, R. L., Thakur, G. A., & Imad, M. (2017). The interaction between alpha 7 nicotinic acetylcholine receptor and nuclear peroxisome proliferator-activated receptor-α represents a new antinociceptive signaling pathway in mice. Experimental Neurology, 295, 194-201. https://doi.org/10.1016/j.expneurol.2017.06.014
Fidaleo, M., Fanelli, F., Ceru, M., & Moreno, S. (2014). Neuroprotective properties of peroxisome proliferator-activated receptor alpha (PPARα) and its lipid ligands. Current Medicinal Chemistry, 21(24), 2803-2821. https://doi.org/10.2174/0929867321666140303143455
Fu, J., Oveisi, F., Gaetani, S., Lin, E., & Piomelli, D. (2005). Oleoylethanolamide, an endogenous PPAR-alpha agonist, lowers body weight and hyperlipidemia in obese rats. Neuropharmacology, 48(8), 1147-1153. https://doi.org/10.1016/j.neuropharm.2005.02.013
Grygiel-Górniak, B. (2014). Peroxisome proliferator-activated receptors and their ligands: Nutritional and clinical implications-A review. Nutrition Journal, 13, 17. https://doi.org/10.1186/1475-2891-13-17
Hambrecht-Wiedbusch, V. S., Mitchell, M. F., Firn, K. A., Baghdoyan, H. A., & Lydic, R. (2014). Benzodiazepine site agonists differentially alter acetylcholine release in rat amygdala. Anesthesia and Analgesia, 118(6), 1293-1300. https://doi.org/10.1213/ANE.0000000000000201
Hammarlund-Udenaes, M. (2017). Microdialysis as an important technique in systems pharmacology-a historical and methodological review. The AAPS Journal, 19(5), 1294-1303. https://doi.org/10.1208/s12248-017-0108-2
Hanlon, E. C. (2020). Impact of circadian rhythmicity and sleep restriction on circulating endocannabinoid (eCB) N-arachidonoylethanolamine (anandamide). Psychoneuroendocrinology, 111, 104471. https://doi.org/10.1016/j.psyneuen.2019.104471
Holst, S. C., & Landolt, H. P. (2018). Sleep-wake neurochemistry. Sleep Medicine Clinics, 13(2), 137-146. https://doi.org/10.1016/j.jsmc.2018.03.002
Hubrecht, R. C., & Carter, E. (2019). The 3Rs and humane experimental technique: Implementing change. Animals, 9(10), 754. https://doi.org/10.3390/ani9100754
Irmak, S. O., & de Lecea, L. (2014). Basal forebrain cholinergic modulation of sleep transitions. Sleep, 37(12), 1941-1951. https://doi.org/10.5665/sleep.4246
Jones, B. E., & Cuello, A. C. (1989). Afferents to the basal forebrain cholinergic cell area from pontomesencephalic-catecholamine, serotonin, and acetylcholine-neurons. Neuroscience, 31(1), 37-61. https://doi.org/10.1016/0306-4522(89)90029-8
Jumpertz, R., Guijarro, A., Pratley, R. E., Piomelli, D., & Krakoff, J. (2011). Central and peripheral endocannabinoids and cognate acylethanolamides in humans: Association with race, adiposity, and energy expenditure. The Journal of Clinical Endocrinology & Metabolism, 96(3), 787-791. https://doi.org/10.1210/jc.2010-2028
Jumpertz, R., Wiesner, T., Blüher, M., Engeli, S., Bátkai, S., Wirtz, H., Bosse-Henck, A., & Stumvoll, M. (2010). Circulating endocannabinoids and N-acyl-ethanolamides in patients with sleep apnea-Specific role of oleoylethanolamide. Experimental and Clinical Endocrinology & Diabetes, 118(09), 591-595. https://doi.org/10.1055/s-0030-1253344
Kayama, Y., & Koyama, Y. (2003). Control of sleep and wakefulness by brainstem monoaminergic and cholinergic neurons. Acta Neurochirurgica. Supplement, 87, 3-6. https://doi.org/10.1007/978-3-7091-6081-7_1
Kehrer, J. P., Biswal, S. S., La, E., Thuillier, P., Datta, K., Fischer, S. M., & Vanden Heuvel, J. P. (2001). Inhibition of peroxisome-proliferator-activated receptor (PPAR)alpha by MK886. The Biochemical Journal, 356(Pt 3), 899-906. https://doi.org/10.1042/0264-6021:3560899
Koethe, D., Schreiber, D., Giuffrida, A., Mauss, C., Faulhaber, J., Heydenreich, B., Hellmich, M., Graf, R., Klosterkötter, J., Piomelli, D., & Leweke, F. M. (2009). Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid. Journal of Neural Transmission, 116(3), 301-305. https://doi.org/10.1007/s00702-008-0169-6
Kondo, Y., Chikahisa, S., Shiuchi, T., Shimizu, N., Tanioka, D., Uguisu, H., & Séi, H. (2020). Sleep profile during fasting in PPAR-alpha knockout mice. Physiology & Behavior, 214, 112760. https://doi.org/10.1016/j.physbeh.2019.112760
Lama, A., Pirozzi, C., Annunziata, C., Morgese, M. G., Senzacqua, M., Severi, I., Calignano, A., Trabace, L., Giordano, A., Meli, R., & Mattace, G. (2021). Palmitoylethanolamide counteracts brain fog improving depressive-like behaviour in obese mice: Possible role of synaptic plasticity and neurogenesis. British Journal of Pharmacology, 178(4), 845-859. https://doi.org/10.1111/bph.15071
Leenaars, C. H. C., Freymann, J., Jakobs, K., Menon, J. M. L., Van Ee, T. J., Elzinga, J., Kempkes, R. W. M., Zoer, B., & Drinkenburg, P. W. H. I. M. (2018). A systematic search and mapping review of studies on intracerebral microdialysis of amino acids, and systematized review of studies on circadian rhythms. Journal of Circadian Rhythms, 16, 12. https://doi.org/10.5334/jcr.172
Li, Y. D., Luo, Y. J., Xu, W., Ge, J., Cherasse, Y., Wang, Y. Q., Lazarus, M., Qu, W. M., & Huang, Z. L. (2020). Ventral pallidal GABAergic neurons control wakefulness associated with motivation through the ventral tegmental pathway. Molecular Psychiatry. https://doi.org/10.1038/s41380-020-00906-0
Luppi, P. H., & Fort, P. (2019). Sleep-wake physiology. In K. H. Levin & P. Chauvel Handbook of clinical neurology (Vol. 160, pp. 359-370). Elsevier. https://doi.org/10.1016/B978-0-444-64032-1.00023-0
Melis, M., Pillolla, G., Luchicchi, A., Muntoni, A. L., Yasar, S., Goldberg, S. R., & Pistis, M. (2008). Endogenous fatty acid ethanolamides suppress nicotine-induced activation of mesolimbic dopamine neurons through nuclear receptors. The Journal of Neuroscience, 28(51), 13985-13994. https://doi.org/10.1523/JNEUROSCI.3221-08.2008
Mennella, I., Boudry, G., & Val-Laillet, D. (2019). Ethanolamine produced from oleoylethanolamide degradation contributes to acetylcholine/dopamine balance modulating eating behavior. The Journal of Nutrition, 149(3), 362-365. https://doi.org/10.1093/jn/nxy281
Mijangos-Moreno, S., Poot-Aké, A., Guzmán, K., Arankowsky-Sandoval, G., Arias-Carrión, O., Zaldívar-Rae, J., Sarro-Ramírez, A., & Murillo-Rodríguez, E. (2016). Sleep and neurochemical modulation by the nuclear peroxisome proliferator-activated receptor α (PPAR-α) in rat. Neuroscience Research, 105, 65-69. https://doi.org/10.1016/j.neures.2015.09.005
Morin, L. P., & Meyer-Bernstein, E. L. (1999). The ascending serotonergic system in the hamster: Comparison with projections of the dorsal and median raphe nuclei. Neuroscience, 91(1), 81-105. https://doi.org/10.1016/s0306-4522(98)00585-5
Moszczynski, A., & Murray, B. J. (2012). Neurobiological aspects of sleep physiology. Neurologic Clinics, 30(4), 963-985. https://doi.org/10.1016/j.ncl.2012.08.001
Murillo-Rodriguez, E. (2017). The role of nuclear receptor PPARα in the sleep-wake cycle modulation. A tentative approach for treatment of sleep disorders. Current Drug Delivery, 14(4), 473-482. https://doi.org/10.2174/1567201814666161109123803
Murillo-Rodríguez, E., Arankowsky-Sandoval, G., Barros, J. A., Rocha, N. B., Yamamoto, T., Machado, S., Budde, H., Telles-Correia, D., Monteiro, D., Cid, L., & Veras, A. B. (2019). Sleep and neurochemical modulation by DZNep and GSK-J1: Potential link with histone methylation status. Frontiers in Neuroscience, 13, 237. https://doi.org/10.3389/fnins.2019.00237
Murillo-Rodríguez, E., Arankowsky-Sandoval, G., Pertwee, R. G., Parker, L., & Mechoulam, R. (2020). Sleep and neurochemical modulation by cannabidiolic acid methyl ester in rats. Brain Research Bulletin, 155, 166-173. https://doi.org/10.1016/j.brainresbull.2019.12.006
Murillo-Rodríguez, E., Arankowsky-Sandoval, G., Rocha, N. B., Peniche-Amante, R., Veras, A. B., Machado, S., & Budde, H. (2018). Systemic injections of cannabidiol enhance acetylcholine levels from basal forebrain in rats. Neurochemical Research, 43(8), 1511-1518. https://doi.org/10.1007/s11064-018-2565-0
Murillo-Rodriguez, E., Blanco-Centurion, C., Gerashchenko, D., Salin-Pascual, R. J., & Shiromani, P. J. (2004). The diurnal rhythm of adenosine levels in the basal forebrain of young and old rats. Neuroscience, 123(2), 361-370. https://doi.org/10.1016/j.neuroscience.2003.09.015
Murillo-Rodríguez, E., Désarnaud, F., & Prospéro-García, O. (2006). Diurnal variation of arachidonoylethanolamine, palmitoylethanolamide and oleoylethanolamide in the brain of the rat. Life Sciences, 79(1), 30-37. https://doi.org/10.1016/j.lfs.2005.12.028
Murillo-Rodríguez, E., Guzmán, K., Arankowsky-Sandoval, G., Salas-Crisóstomo, M., Jiménez-Moreno, R., & Arias-Carrión, O. (2016). Evidence that activation of nuclear peroxisome proliferator-activated receptor alpha (PPARα) modulates sleep homeostasis in rats. Brain Research Bulletin, 127, 156-163. https://doi.org/10.1016/j.brainresbull.2016.09.007
Murillo-Rodríguez, E., Palomero-Rivero, M., Millán-Aldaco, D., Arias-Carrión, O., & Drucker-Colín, R. (2011). Administration of URB597, oleoylethanolamide or palmitoylethanolamide increases waking and dopamine in rats. PLoS ONE, 6(7), e20766. https://doi.org/10.1371/journal.pone.0020766
Murillo-Rodríguez, E., Vázquez, E., Millán-Aldaco, D., Palomero-Rivero, M., & Drucker-Colin, R. (2007). Effects of the fatty acid amide hydrolase inhibitor URB597 on the sleep-wake cycle, c-Fos expression and dopamine levels of the rat. European Journal of Pharmacology, 562(1-2), 82-91. https://doi.org/10.1016/j.ejphar.2007.01.076
Nabavi, S. M., Devi, K. P., Sathya, S., Sanches-Silva, A., Joanna, L., Talarek, S., Xu, S., Daglia, M., Nabavi, S. F., Shirooie, S., Sureda, A., Tejada, S., Banach, M., Dehpour, A. R., & Saso, L. (2020). New trends in the pharmacological intervention of PPARs in obesity: Role of natural and synthetic compounds_. Current Medicinal Chemistry, 28, 4004-4022. https://doi.org/10.2174/1570162x18666201123114934
Nisbett, K. E., & Pinna, G. (2018). Emerging therapeutic role of PPAR-α in cognition and emotions. Frontiers in Pharmacology, 9, 998. https://doi.org/10.3389/fphar.2018.00998
Onesti, E., Frasca, V., Ceccanti, M., Tartaglia, G., Gori, M. C., Cambieri, C., Libonati, L., Palma, E., & Inghilleri, M. (2019). Short-term ultramicronized palmitoylethanolamide therapy in patients with myasthenia gravis: A pilot study to possible future implications of treatment. CNS & Neurological Disorders Drug Targets, 18(3), 232-238. https://doi.org/10.2174/1871527318666190131121827
Paxinos, G., & Watson, C. (2005). The rat brain in stereotaxic coordinates. San Diego, CA, USA: Academic Press.
Prospéro-García, O., Amancio-Belmont, O., Becerril Meléndez, A. L., Ruiz-Contreras, A. E., & Méndez-Díaz, M. (2016). Endocannabinoids and sleep. Neuroscience & Biobehavioral Reviews, 71, 671-679. https://doi.org/10.1016/j.neubiorev.2016.10.005
Puligheddu, M., Pillolla, G., Melis, M., Lecca, S., Marrosu, F., De Montis, M. G., Scheggi, S., Carta, G., Murru, E., Aroni, S., Muntoni, A. L., & Pistis, M. (2013). PPAR-alpha agonists as novel antiepileptic drugs: Preclinical findings. PLoS ONE, 8(5), e64541. https://doi.org/10.1371/journal.pone.0064541
Ren, J., Isakova, A., Friedmann, D., Zeng, J., Grutzner, S. M., Pun, A., Zhao, G. Q., Kolluru, S. S., Wang, R., Lin, R., Li, P., Li, A., Raymond, J. L., Luo, Q., Luo, M., Quake, S. R., & Luo, L. (2019). Single-cell transcriptomes and whole-brain projections of serotonin neurons in the mouse dorsal and median raphe nuclei. eLife, 8, e49424. https://doi.org/10.7554/eLife.49424
Rodríguez de Fonseca, F., Navarro, M., Gómez, R., Escuredo, L., Nava, F., Fu, J., Murillo-Rodríguez, E., Giuffrida, A., LoVerme, J., Gaetani, S., Kathuria, S., Gall, C., & Piomelli, D. (2001). An anorexic lipid mediator regulated by feeding. Nature, 414(6860), 209-212. https://doi.org/10.1038/35102582
Romano, A., Micioni Di Bonaventura, M. V., Gallelli, C. A., Koczwara, J. B., Smeets, D., Giusepponi, M. E., De Ceglia, M., Friuli, M., Micioni Di Bonaventura, E., Scuderi, C., Vitalone, A., Tramutola, A., Altieri, F., Lutz, T. A., Giudetti, A. M., Cassano, T., Cifani, C., & Gaetani, S. (2020). Oleoylethanolamide decreases frustration stress-induced binge-like eating in female rats: A novel potential treatment for binge eating disorder. Neuropsychopharmacology, 45(11), 1931-1941. https://doi.org/10.1038/s41386-020-0686-z
Root, D. H., Melendez, R. I., Zaborszky, L., & Napier, T. C. (2015). The ventral pallidum: Subregion-specific functional anatomy and roles in motivated behaviors. Progress in Neurobiology, 130, 29-70. https://doi.org/10.1016/j.pneurobio.2015.03.005
Rye, D. B., Wainer, B. H., Mesulam, M. M., Mufson, E. J., & Saper, C. B. (1984). Cortical projections arising from the basal forebrain: A study of cholinergic and noncholinergic components employing combined retrograde tracing and immunohistochemical localization of choline acetyltransferase. Neuroscience, 13(3), 627-643. https://doi.org/10.1016/0306-4522(84)90083-6
Schäble, S., Topic, B., Buddenberg, T., Petri, D., Huston, J. P., & de Souza Silva, M. A. (2011). Neurokinin3-R agonism in aged rats has anxiolytic-, antidepressant-, and promnestic-like effects and stimulates ACh release in frontal cortex, amygdala and hippocampus. European Neuropsychopharmacology, 21(6), 484-494. https://doi.org/10.1016/j.euroneuro.2010.11.010
Soria-Gómez, E., Guzmán, K., Pech-Rueda, O., Montes-Rodríguez, C., Cisneros, M., & Prospéro-García, O. (2010). Oleoylethanolamide affects food intake and sleep-waking cycle through a hypothalamic modulation. Pharmacological Research, 61(5), 379-384. https://doi.org/10.1016/j.phrs.2010.01.010
Spaner, D. E., Lee, E., Shi, Y., Wen, F., Li, Y., Tung, S., McCaw, L., Wong, K., Gary-Gouy, H., Dalloul, A., Ceddia, R., & Gorzcynski, R. (2013). PPAR-alpha is a therapeutic target for chronic lymphocytic leukemia. Leukemia, 27(5), 1090-1099. https://doi.org/10.1038/leu.2012.329
Tan, Y., Wang, M., Yang, K., Chi, T., Liao, Z., & Wei, P. (2021). PPAR-α modulators as current and potential cancer treatments. Frontiers in Oncology, 11, 599995. https://doi.org/10.3389/fonc.2021.599995
Tutunchi, H., Naeini, F., Saghafi-Asl, M., Farrin, N., Monshikarimi, A., & Ostadrahimi, A. (2020). Effects of oleoylethanolamide supplementation on atherogenic indices and hematological parameters in patients with nonalcoholic fatty liver disease: A clinical trial. Health Promotion Perspective, 10(4), 373-382. https://doi.org/10.34172/hpp.2020.56
Tutunchi, H., Ostadrahimi, A., Saghafi-Asl, M., Hosseinzadeh-Attar, M. J., Shakeri, A., Asghari-Jafarabadi, M., Roshanravan, N., Farrin, N., Naemi, M., & Hasankhani, M. (2020). Oleoylethanolamide supplementation in obese patients newly diagnosed with non-alcoholic fatty liver disease: Effects on metabolic parameters, anthropometric indices, and expression of PPAR-α, UCP1, and UCP2 genes. Pharmacological Research, 156, 104770. https://doi.org/10.1016/j.phrs.2020.104770
Tutunchi, H., Ostadrahimi, A., Saghafi-Asl, M., & Maleki, V. (2019). The effects of oleoylethanolamide, an endogenous PPAR-α agonist, on risk factors for NAFLD: A systematic review. Obesity Reviews, 20(7), 1057-1069. https://doi.org/10.1111/obr.12853
Tutunchi, H., Ostadrahimi, A., Saghafi-Asl, M., Roshanravan, N., Shakeri-Bavil, A., Asghari-Jafarabadi, M., Farrin, N., & Mobasseri, M. (2020). Expression of NF-κB, IL-6, and IL-10 genes, body composition, and hepatic fibrosis in obese patients with NAFLD-Combined effects of oleoylethanolamide supplementation and calorie restriction: A triple-blind randomized controlled clinical trial. Journal of Cellular Physiology, 236(1), 417-426. https://doi.org/10.1002/jcp.29870
Tutunchi, H., Saghafi-Asl, M., & Ostadrahimi, A. (2020). A systematic review of the effects of oleoylethanolamide, a high-affinity endogenous ligand of PPAR-α, on the management and prevention of obesity. Clinical and Experimental Pharmacology & Physiology, 47(4), 543-552. https://doi.org/10.1111/1440-1681.13238
Tyagi, S., Gupta, P., Saini, A. S., Kaushal, C., & Sharma, S. (2011). The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases. Journal of Advanced Pharmaceutical Technology & Research, 2(4), 236-240. https://doi.org/10.4103/2231-4040.90879
Vaughn, L. K., Denning, G., Stuhr, K. L., de Wit, H., Hill, M. N., & Hillard, C. J. (2010). Endocannabinoid signalling: Has it got rhythm? British Journal of Pharmacology, 160(3), 530-543. https://doi.org/10.1111/j.1476-5381.2010.00790.x
Villano, I., Messina, A., Valenzano, A., Moscatelli, F., Esposito, T., Monda, V., Esposito, M., Precenzano, F., Carotenuto, M., Viggiano, A., Chieffi, S., Cibelli, G., Monda, M., & Messina, G. (2017). Basal forebrain cholinergic system and orexin neurons: Effects on attention. Frontiers in Behavioral Neuroscience, 11, 10. https://doi.org/10.3389/fnbeh.2017.00010
Wagner, K. D., & Wagner, N. (2020a). PPARs and myocardial infarction. International Journal of Molecular Sciences, 21(24), 9436. https://doi.org/10.3390/ijms21249436
Wagner, N., & Wagner, K. D. (2020b). The role of PPARs in disease. Cell, 9(11), 2367. https://doi.org/10.3390/cells9112367
Wang, H., Jiang, R., He, Q., Zhang, Y., Zhang, Y., Li, Y., Zhuang, R., Luo, Y., Li, Y., Wan, J., Tang, Y., Yu, H., Jiang, Q., & Yang, J. (2012). Expression pattern of peroxisome proliferator-activated receptors in rat hippocampus following cerebral ischemia and reperfusion injury. PPAR Research, 2012, 596394. https://doi.org/10.1155/2012/596394
Warden, A., Truitt, J., Merriman, M., Ponomareva, O., Jameson, K., Ferguson, L. B., Mayfield, R. D., & Harris, R. A. (2016). Localization of PPAR isotypes in the adult mouse and human brain. Scientific Reports, 6, 27618. https://doi.org/10.1038/srep27618
Wójtowicz, S., Strosznajder, A. K., Jeżyna, M., & Strosznajder, J. B. (2020). The novel role of PPAR alpha in the brain: Promising target in therapy of Alzheimer's disease and other neurodegenerative disorders. Neurochemical Research, 45(5), 972-988. https://doi.org/10.1007/s11064-020-02993-5
Xing, G., Zhang, L., Zhang, L., Heynen, T., Yoshikawa, T., Smith, M., Weiss, S., & Detera-Wadleigh, S. (1995). Rat PPAR delta contains a CGG triplet repeat and is prominently expressed in the thalamic nuclei. Biochemical and Biophysical Research Communications, 217(3), 1015-1025. https://doi.org/10.1006/bbrc.1995.2871
Xu, M., Chung, S., Zhang, S., Zhong, P., Ma, C., Chang, W. C., Weissbourd, B., Sakai, N., Luo, L., Nishino, S., & Dan, Y. (2015). Basal forebrain circuit for sleep-wake control. Nature Neuroscience, 18(11), 1641-1647. https://doi.org/10.1038/nn.4143
Yu, H. L., Sun, L. P., Li, M. M., & Quan, Z. S. (2015). Involvement of norepinephrine and serotonin system in antidepressant-like effects of oleoylethanolamide in the mice models of behavior despair. Neuroscience Letters, 593, 24-28. https://doi.org/10.1016/j.neulet.2015.03.019
Zant, J. C., Kim, T., Prokai, L., Szarka, S., McNally, J., McKenna, J. T., Shukla, C., Yang, C., Kalinchuk, A. V., McCarley, R. W., Brown, R. E., & Basheer, R. (2016). Cholinergic neurons in the basal forebrain promote wakefulness by actions on neighboring non-cholinergic neurons: An opto-dialysis study. The Journal of Neuroscience, 36(6), 2057-2067. https://doi.org/10.1523/JNEUROSCI.3318-15.2016
Zhang, X., Liu, Y., Yang, B., & Xu, H. (2020). Inactivation of the ventral pallidum by GABAA receptor agonist promotes non-rapid eye movement sleep in rats. Neurochemical Research, 45(8), 1791-1801. https://doi.org/10.1007/s11064-020-03040-z